{"title":"68ga - pentxafor用于淋巴增生性疾病和实体肿瘤趋化因子受体4表达的PET成像。","authors":"Tingwei Meng, Qingqing Pan, Yaping Luo","doi":"10.1967/s002449912803","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Gallium-68 (<sup>68</sup>Ga)-pentixafor, a novel positron emission tomography (PET) tracer with high affinity for C-X-C motif chemokine receptor 4 (CXCR4), has recently been introduced in order to assess the CXCR4 expression status in vivo. This study is to investigate the role of <sup>68</sup>Ga-pentixafor in detecting various tumors with mice models and to provide references to clinical studies.</p><p><strong>Materials and methods: </strong>Gallium-68-pentixafor and fluorine-18-fluorodeoxyglucose (<sup>18</sup>F-FDG) PET was performed in opm-2 (lymphoma), daudi (myeloma) and panc1 (pancreatic cancer)-bearing mice. Tumor and background tissue uptake between <sup>68</sup>Ga-pentixafor and <sup>18</sup>F-FDG PET were compared. Gallium-68-pentixafor PET/computed tomography (CT) was performed in four patients with lymphoma and three patients with multiple myeloma, and <sup>18</sup>F-FDG PET/CT was performed as a reference.</p><p><strong>Results: </strong>The uptake of <sup>68</sup>Ga-pentixafor in background tissues including muscle, liver and kidneys were all lower than those of <sup>18</sup>F-FDG. The uptake of <sup>68</sup>Ga-pentixafor in the tumors of lymphoma and myeloma-bearing xenografts was comparable or higher than those of <sup>18</sup>F-FDG. However, the tumors of panc-1 xenografts had much lower uptake of <sup>68</sup>Ga-pentixafor than those in lymphoma and myeloma-bearing mice, and it was also significantly lower than those of <sup>18</sup>F-FDG. The high uptake of <sup>68</sup>Ga-pentixafor in vivo was confirmed by the high expression of CXCR4 in tumors with immunochemical analysis. Gallium-68-pentixafor PET/CT in patients with marginal zone lymphoma (MZL) and myeloma showed more intense uptake and more extensive involvement than <sup>18</sup>F-FDG PET/CT did. Gallium-68-pentixafor and <sup>18</sup>F-FDG PET/CT showed comparable uptake in the patient with follicular lymphoma.</p><p><strong>Conclusion: </strong>Gallium-68-pentixafor is a promising agent for the evaluation of lymphoproliferative diseases.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"124-130"},"PeriodicalIF":1.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"<sup>68</sup>Ga-pentixafor for PET imaging of chemokine receptor 4 expression in lymphoproliferative diseases and solid tumors.\",\"authors\":\"Tingwei Meng, Qingqing Pan, Yaping Luo\",\"doi\":\"10.1967/s002449912803\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Gallium-68 (<sup>68</sup>Ga)-pentixafor, a novel positron emission tomography (PET) tracer with high affinity for C-X-C motif chemokine receptor 4 (CXCR4), has recently been introduced in order to assess the CXCR4 expression status in vivo. This study is to investigate the role of <sup>68</sup>Ga-pentixafor in detecting various tumors with mice models and to provide references to clinical studies.</p><p><strong>Materials and methods: </strong>Gallium-68-pentixafor and fluorine-18-fluorodeoxyglucose (<sup>18</sup>F-FDG) PET was performed in opm-2 (lymphoma), daudi (myeloma) and panc1 (pancreatic cancer)-bearing mice. Tumor and background tissue uptake between <sup>68</sup>Ga-pentixafor and <sup>18</sup>F-FDG PET were compared. Gallium-68-pentixafor PET/computed tomography (CT) was performed in four patients with lymphoma and three patients with multiple myeloma, and <sup>18</sup>F-FDG PET/CT was performed as a reference.</p><p><strong>Results: </strong>The uptake of <sup>68</sup>Ga-pentixafor in background tissues including muscle, liver and kidneys were all lower than those of <sup>18</sup>F-FDG. The uptake of <sup>68</sup>Ga-pentixafor in the tumors of lymphoma and myeloma-bearing xenografts was comparable or higher than those of <sup>18</sup>F-FDG. However, the tumors of panc-1 xenografts had much lower uptake of <sup>68</sup>Ga-pentixafor than those in lymphoma and myeloma-bearing mice, and it was also significantly lower than those of <sup>18</sup>F-FDG. The high uptake of <sup>68</sup>Ga-pentixafor in vivo was confirmed by the high expression of CXCR4 in tumors with immunochemical analysis. Gallium-68-pentixafor PET/CT in patients with marginal zone lymphoma (MZL) and myeloma showed more intense uptake and more extensive involvement than <sup>18</sup>F-FDG PET/CT did. Gallium-68-pentixafor and <sup>18</sup>F-FDG PET/CT showed comparable uptake in the patient with follicular lymphoma.</p><p><strong>Conclusion: </strong>Gallium-68-pentixafor is a promising agent for the evaluation of lymphoproliferative diseases.</p>\",\"PeriodicalId\":12871,\"journal\":{\"name\":\"Hellenic journal of nuclear medicine\",\"volume\":\" \",\"pages\":\"124-130\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hellenic journal of nuclear medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1967/s002449912803\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hellenic journal of nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1967/s002449912803","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/4 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
68Ga-pentixafor for PET imaging of chemokine receptor 4 expression in lymphoproliferative diseases and solid tumors.
Objective: Gallium-68 (68Ga)-pentixafor, a novel positron emission tomography (PET) tracer with high affinity for C-X-C motif chemokine receptor 4 (CXCR4), has recently been introduced in order to assess the CXCR4 expression status in vivo. This study is to investigate the role of 68Ga-pentixafor in detecting various tumors with mice models and to provide references to clinical studies.
Materials and methods: Gallium-68-pentixafor and fluorine-18-fluorodeoxyglucose (18F-FDG) PET was performed in opm-2 (lymphoma), daudi (myeloma) and panc1 (pancreatic cancer)-bearing mice. Tumor and background tissue uptake between 68Ga-pentixafor and 18F-FDG PET were compared. Gallium-68-pentixafor PET/computed tomography (CT) was performed in four patients with lymphoma and three patients with multiple myeloma, and 18F-FDG PET/CT was performed as a reference.
Results: The uptake of 68Ga-pentixafor in background tissues including muscle, liver and kidneys were all lower than those of 18F-FDG. The uptake of 68Ga-pentixafor in the tumors of lymphoma and myeloma-bearing xenografts was comparable or higher than those of 18F-FDG. However, the tumors of panc-1 xenografts had much lower uptake of 68Ga-pentixafor than those in lymphoma and myeloma-bearing mice, and it was also significantly lower than those of 18F-FDG. The high uptake of 68Ga-pentixafor in vivo was confirmed by the high expression of CXCR4 in tumors with immunochemical analysis. Gallium-68-pentixafor PET/CT in patients with marginal zone lymphoma (MZL) and myeloma showed more intense uptake and more extensive involvement than 18F-FDG PET/CT did. Gallium-68-pentixafor and 18F-FDG PET/CT showed comparable uptake in the patient with follicular lymphoma.
Conclusion: Gallium-68-pentixafor is a promising agent for the evaluation of lymphoproliferative diseases.
期刊介绍：
The Hellenic Journal of Nuclear Medicine published by the Hellenic Society of
Nuclear Medicine in Thessaloniki, aims to contribute to research, to education and
cover the scientific and professional interests of physicians, in the field of nuclear
medicine and in medicine in general. The journal may publish papers of nuclear
medicine and also papers that refer to related subjects as dosimetry, computer science,
targeting of gene expression, radioimmunoassay, radiation protection, biology, cell
trafficking, related historical brief reviews and other related subjects. Original papers
are preferred. The journal may after special agreement publish supplements covering
important subjects, dully reviewed and subscripted separately.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
